Navigation Links
Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
Date:12/14/2007


Worldwide Rights for All Potential Uses, Excluding U.S. and Japan

No Other Existing Therapeutic Treatment for Celiac Disease

BASINGSTOKE, England and PHILADELPHIA, December 14 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announces that it has acquired the worldwide rights, excluding the U.S. and Japan, to AT-1001 from Alba Therapeutics Corporation (Alba). AT-1001 is Alba's lead inhibitor of barrier dysfunction in various gastrointestinal disorders that is currently in Phase 2 development for the treatment of Celiac disease. Shire has acquired rights to all uses for AT-1001, which may also be studied for the treatment of Crohn's disease and other indications.

Matthew Emmens, Chief Executive Officer, commented: "The licensing of AT-1001 from Alba is a natural fit to our growing portfolio of gastrointestinal products. This product will be marketed to specialist physicians and we would expect to use our existing European sales force that is currently establishing relationships and expertise in the GI area through the marketing of MEZAVANT XL."

Financial terms of the license are geared to the successful development and commercialization of the product. Shire will pay Alba an upfront license fee of $25 million and further development and sales-based milestones totalling to a maximum of $300.5M should the product reach blockbuster status. Shire will also pay royalties on net sales of the product, with tiered, single or double digit royalty rates.

Alba and Shire will form a joint development committee to monitor R&D activities of AT-1001. Alba will fund all development until AT-1001 has completed Proof of Concept, which is expected to be in the first half of 2009, after which Shire and Alba will share equally development costs under a joint development plan.

About Celiac disease:

Celiac disease is a T-cell mediated auto-immune dis
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. ATS Medical Expands Open Pivot Heart Valve Offerings
9. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
10. BioLife Solutions Expands Scientific Advisory Board
11. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Array BioPharma Inc. (NASDAQ: ARRY ... agreement with Novartis Pharma AG to acquire worldwide rights ... 3 development.  This agreement is conditional on the closing of ... 22, 2014, which are expected to close in the ...
(Date:1/22/2015)... | RBJ today announces the firm brokered a long-term lease ... leading biopharmaceutical company, at Two Ledgemont Center in ... , president, and Brian Cohen , senior vice president, ... at 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... 2015 The laboratory information management systems ... a number of technological advancements due to factors such ... need to integrate healthcare systems, and increasing government support ... system integration. Key players in the market focus on ...
(Date:1/22/2015)... 2015 zFlo Motion , a US ... an exciting product from a new partner. STT-Systems ... the past 15 years, with offerings in the optical-motion capture, ... IMU system (inertial measurement unit), iSen, is opening eyes around ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 43D Motion Capture Just Got Easy 2
... Aug. 7 SGX Pharmaceuticals,(Nasdaq: SGXP ) today announced ... 30, 2008. For the three months ended June 30, 2008, ... of $7.2 million. For,the six months ended June 30, 2008, ... The revenue in the six month period includes $10.8,million of ...
... SOUTH SAN FRANCISCO, Calif., Aug. 7 Anesiva,Inc. (Nasdaq: ... the second quarter and six months ended June 30, ... advance for Anesiva as we,introduced Zingo(TM) in the U.S. ... executive officer. "In addition, I,m pleased,to report that our ...
... Chromos Molecular,Systems Inc. ("Chromos" or the "Company") announced ... (the "Arrangement Agreement") dated,August 6, 2008 with, among ... Chromos, and Modatech Systems Inc. ("Modatech"),pursuant to which ... effect a plan,of arrangement (the "Arrangement") under section ...
Cached Biology Technology:SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 2SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 3SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 4SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 5SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 6SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 7SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 8SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 9Anesiva Announces Second Quarter 2008 Financial Results and Update 2Anesiva Announces Second Quarter 2008 Financial Results and Update 3Anesiva Announces Second Quarter 2008 Financial Results and Update 4Anesiva Announces Second Quarter 2008 Financial Results and Update 5Anesiva Announces Second Quarter 2008 Financial Results and Update 6Anesiva Announces Second Quarter 2008 Financial Results and Update 7Anesiva Announces Second Quarter 2008 Financial Results and Update 8Chromos enters into an Arrangement Agreement 2Chromos enters into an Arrangement Agreement 3
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ...
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched an innovative ... that enhances care coordination among social service and care providers ... second $1 million grant from the Alliance Healthcare Foundation to ... be recognized as a "Live Well San Diego" partner on ...
(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... 6 December 2007 Elsevier is pleased to announce ... Leukotrienes & Essential Fatty Acids (PLEFA) will become the ... of Fatty Acids and Lipids (ISSFAL). 2008 ... in 1978 as Prostaglandins and Medicine by the late ...
... could solve the growing energy demands of millions of ... the region,s tensions pertaining to oil supplies through hydroelectric ... untold ecological harm and displace countless people from their ... Global Environmental Issues, Roelof Dirk Schuiling of Utrecht University ...
... in a Fully Flexible ... ISO-Compliant ... Microsystems, Inc., a,pioneering developer of fingerprint imaging and authentication ... Card. This biometrically-authenticated credential,features a fully-embedded biometric system. Fidelica,s ...
Cached Biology News:Dam the Red Sea and release gigawatts 2Fidelica Microsystems Announces Biometrically-Authenticated Smart Card 2
Mouse Anti-Amyloid beta [1-16], clone 6E10, Monoclonal Antibody...
... Development kit contains the basic components required ... measure natural and recombinant mouse Dickkopf homolog-1 ... Each kit contains sufficient materials to run ... that the following conditions are met: ...
HES-1 [Hairy 1], Available Summer 2003...
E1A (adenovirus early region 1)...
Biology Products: